OVERVIEW - PIPELINE

Robust Development Pipeline & Partnerships

Programs

Oncology

MLL-Menin

(Leukemia)

Yap-Tead*

(Solid Tumors)

STING*

(Tumor Myeloid cells)

RAS*

(Protein Degradation)

Additional Programs

CLK

(Cancer & DMD)

LpxC

(Gram - Bacteria)

Collaboration

Cardiovascular

Oncology

Target

Identification

In-Silico

Pre-Optimization

Synthesis

Testing

Pre-IND

Studies

Lead

Identification

Lead

Optimization

IND

Potential

Market

2019

2021

 

2022

 

 

2022

 

 

 

2020

 

 

2021

$1B

$5B

$1B

$5B

$3B

$1B

Partnerships with Novartis and Proctor & Gamble to design drug candidates for cardiavascular and cancer targest

menu
Contact

BioLabs New York
180 Varick Street
New York, NY 10014

​​

Cambridge Innovation Center
1 Broadway 
Cambridge, MA 02142
Boston

Info@Atoms2applications.com

© 2019 A2A Pharma. All rights reserved